1279029-70-7Relevant articles and documents
General Fmoc-Based Solid-Phase Synthesis of Complex Depsipeptides Circumventing Problematic Fmoc Removal
Lobo-Ruiz, Ariadna,Tulla-Puche, Judit
, p. 183 - 192 (2020)
Development of an Fmoc-based solid-phase depsipeptide methodology has been hampered by base-promoted fragmentation and diketoperazine formation upon Fmoc group elimination. Such a strategy would be a useful tool given the number of commercially available Fmoc-protected residues. Herein we report that the addition of small percentages of organic acids to the Fmoc-removal cocktail proves effective to circumvent these drawbacks and most importantly, allowed the development of an exclusively solid-phase stepwise methodology to prepare a highly complex depsipeptide with multiple and consecutive esters bonds. Alongside, the optimal protecting group scheme for residue incorporation, which is not as straightforward as it is for traditional peptide synthesis, was explored. The developed stepwise strategy proved effective for the synthesis of a highly complex cyclodepsipeptide, being comparable to the yields obtained when using traditional combined chemistry approaches.
Angiotensin-1-Receptor Antagonists
-
Paragraph 0056, (2018/01/09)
In one aspect, this disclosure features compounds of formula (I) or a pharmaceutically acceptable salt thereof: [in-line-formulae]AA1-Arg-Val-AA4-AA5-His-Pro-AA8-OH ??(I),[/in-line-formulae] in which AA1, AA4, AA5, and AA8 are defined in the specification. The compounds of formula (I) can be used to treat hypertension (e.g., hypertension induced by pregnancy), preeclampsia, or a renal disease induced by pregnancy.
